TW200744664A - Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis - Google Patents

Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis

Info

Publication number
TW200744664A
TW200744664A TW095135667A TW95135667A TW200744664A TW 200744664 A TW200744664 A TW 200744664A TW 095135667 A TW095135667 A TW 095135667A TW 95135667 A TW95135667 A TW 95135667A TW 200744664 A TW200744664 A TW 200744664A
Authority
TW
Taiwan
Prior art keywords
composition containing
treatment
pharmaceutical composition
herpetic keratitis
containing brivudine
Prior art date
Application number
TW095135667A
Other languages
English (en)
Inventor
Marc Wihsmann
Reinhard Schmitz
Original Assignee
Berlin Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie Ag filed Critical Berlin Chemie Ag
Publication of TW200744664A publication Critical patent/TW200744664A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW095135667A 2005-09-29 2006-09-27 Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis TW200744664A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005046769A DE102005046769A1 (de) 2005-09-29 2005-09-29 Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus)

Publications (1)

Publication Number Publication Date
TW200744664A true TW200744664A (en) 2007-12-16

Family

ID=37561306

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095135667A TW200744664A (en) 2005-09-29 2006-09-27 Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis

Country Status (33)

Country Link
US (1) US20080249061A1 (zh)
EP (1) EP1940353B1 (zh)
JP (1) JP2009509993A (zh)
KR (1) KR20080053319A (zh)
CN (1) CN101272765A (zh)
AP (1) AP2008004394A0 (zh)
AR (1) AR056551A1 (zh)
AT (1) ATE489076T1 (zh)
AU (1) AU2006299115A1 (zh)
BR (1) BRPI0616449A2 (zh)
CA (1) CA2624111A1 (zh)
CR (1) CR9839A (zh)
CY (1) CY1111059T1 (zh)
DE (2) DE102005046769A1 (zh)
DK (1) DK1940353T3 (zh)
EA (1) EA012975B1 (zh)
EC (1) ECSP088310A (zh)
ES (1) ES2356774T3 (zh)
HN (1) HN2008000497A (zh)
HR (1) HRP20110085T1 (zh)
IL (1) IL190466A0 (zh)
MA (1) MA29887B1 (zh)
NO (1) NO20081488L (zh)
PE (1) PE20070767A1 (zh)
PL (1) PL1940353T3 (zh)
PT (1) PT1940353E (zh)
RS (1) RS51615B (zh)
SI (1) SI1940353T1 (zh)
TN (1) TNSN08094A1 (zh)
TW (1) TW200744664A (zh)
UA (1) UA90911C2 (zh)
WO (1) WO2007039201A2 (zh)
ZA (1) ZA200802729B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006130A2 (en) * 2007-06-28 2009-01-08 Bausch & Lomb Incorporated Salt free hyaluronate ophthalmic solution
US20090196833A1 (en) * 2008-02-06 2009-08-06 Adherex Technologies Inc. Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome
DE102009003942A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
PT2898888T (pt) 2014-01-22 2019-07-16 Visufarma B V Composição que compreende iota-carragenina contra conjuntivite viral
BR112018072647A2 (pt) * 2016-05-06 2019-02-19 SaCSh Corp. composições oftálmicas
CN113712928A (zh) * 2021-09-29 2021-11-30 重庆市力扬医药开发有限公司 经口腔粘膜吸收的溴夫定药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY136633A (en) * 2001-01-17 2008-11-28 Berlin Chemie Ag Stabilized brivudine topical formulations
DE10162593A1 (de) * 2001-12-19 2003-07-03 Menarini Ricerche Spa Stabilisierte topische Brivudin-Formulierungen

Also Published As

Publication number Publication date
HRP20110085T1 (hr) 2011-03-31
DE602006018505D1 (de) 2011-01-05
SI1940353T1 (sl) 2011-03-31
WO2007039201A2 (en) 2007-04-12
NO20081488L (no) 2008-03-26
PL1940353T3 (pl) 2011-05-31
AR056551A1 (es) 2007-10-10
WO2007039201A3 (en) 2007-10-04
IL190466A0 (en) 2008-11-03
KR20080053319A (ko) 2008-06-12
DK1940353T3 (da) 2011-01-24
CN101272765A (zh) 2008-09-24
ECSP088310A (es) 2008-05-30
ATE489076T1 (de) 2010-12-15
PE20070767A1 (es) 2007-08-13
EA200800646A1 (ru) 2008-10-30
US20080249061A1 (en) 2008-10-09
BRPI0616449A2 (pt) 2011-06-21
EP1940353A2 (en) 2008-07-09
PT1940353E (pt) 2011-02-25
JP2009509993A (ja) 2009-03-12
ZA200802729B (en) 2009-09-30
AP2008004394A0 (en) 2008-04-30
UA90911C2 (ru) 2010-06-10
ES2356774T3 (es) 2011-04-13
MA29887B1 (fr) 2008-10-03
EP1940353B1 (en) 2010-11-24
HN2008000497A (es) 2010-09-10
DE102005046769A1 (de) 2007-04-05
CR9839A (es) 2008-10-31
RS51615B (en) 2011-08-31
CA2624111A1 (en) 2007-04-12
CY1111059T1 (el) 2015-06-11
AU2006299115A1 (en) 2007-04-12
TNSN08094A1 (en) 2009-07-14
AU2006299115A2 (en) 2008-05-29
EA012975B1 (ru) 2010-02-26

Similar Documents

Publication Publication Date Title
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
TNSN08094A1 (en) Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis
WO2005115398A3 (en) Hiv integrase inhibitors
AU2003227741A1 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
MX2007014892A (es) Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
WO2010084115A3 (en) Antiviral agents
SG166802A1 (en) Formulation comprising metformin and vildagli ptin
TW200640908A (en) Chemical compounds
WO2006048747A8 (en) Topical pharmaceutical compositions containing an antiacne compound and antibiotic compound
GEP20094834B (en) Macrolides, pharmaceutical compositions containing them and their use for treatment of bacterial infections
EP1864666A4 (en) PROTECTIVE AGENT FOR RETINAL NEURAL CELL CONTAINING A PROSTAGLANDIN F2 ALPHA DERIVATIVE AS ACTIVE INGREDIENT
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2007030361A3 (en) Benzimidazole thiophene compounds as plk inhibitors
WO2009082134A3 (en) Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
WO2008020227A3 (en) Antibacterial pyrrolecarboxamides
WO2006087544A8 (en) Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
SG166105A1 (en) Antifungal composition
WO2007068728A3 (en) N-substituted pyrrolopyridinones active as kinase inhibitors
AU2003230189A1 (en) Oral controlled release pharmaceutical composition containing metaxalone as active agent
GB2456096A (en) Crystalline form of benzothiophene compound and process for preparation thereof
GB0522474D0 (en) A pharmaceutical formulation
UA92180C2 (en) Benzimidazole thiophene compounds as plk inhibitors
PT2089030E (pt) Agente para profilaxia ou tratamento da dependência do álcool e da dependência de substâncias
MX2009013054A (es) Composicion farmaceutica que comprende un sustrato y un revestimiento que contiene un ingrediente activo y alcohol polivinilico.